Not checked for notices yet.
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
Xinsheng Zhu, Liangdong Sun, Nan Song and 23 more
BMC Medicine · 2022
doi:10.1186/s12916-022-02696-4
Cited by papers we hold 1
- Neoadjuvant Chemoimmunotherapy for NSCLC · 2024No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.